insights_auto
Why is AGIO down ३.२३%?
Dive Deeperchevron_right
AGIO:NASDAQ
Agios Pharmaceuticals Inc
US$ ३१.७६
arrow_downward
-३.२३%(-१.०६) 1D
US$ ३१.७६
०.००% (०.००)
bedtimeAfter hours
Closed: नोभेम्बर १२, १६:००:०१ GMT-५ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
US$ ३२.५६
High
US$ ३२.७६
Low
US$ ३१.५६
Mkt. cap
१.९० अरब
Avg. vol.
१२.८९ लाख
Volume
०.००
52-wk high
US$ ४५.९९
52-wk low
US$ २२.२४
EPS
-US$ ६.३२
Beta
०.६६
Shares outstanding
५.९८ करोड
No. of employees
५४०
Open
US$ ३२.५६
High
US$ ३२.७६
Low
US$ ३१.५६
Mkt. cap
१.९० अरब
Avg. vol.
१२.८९ लाख
Volume
०.००
52-wk high
US$ ४५.९९
52-wk low
US$ २२.२४
EPS
-US$ ६.३२
Beta
०.६६
Shares outstanding
५.९८ करोड
No. of employees
५४०
News stories
From web sources and news partners
TradingView
·
१ घण्टा पहिले
Agios Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $47, Implies 48% Upside
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc